Founded by two young chemists in 1945 in Cameri, Italy, Procos S.p.A specializes in developing, scaling up and producing active pharmaceutical ingredients (APIs) and advanced intermediates, as well as providing related services for the global pharmaceutical industry.
In 1952, Procos received its first authorization to manufacture APIs and soon established a solid reputation among the local population for their distinctive products. The company ventured into the global market after it passed its first inspection by the U.S. Food and Drug Administration in 1982.
It wasn’t until after 2006 when Procos was fully acquired by CBC Group that it experienced significant growth. As a wholly owned subsidiary backed by more than 70 years of experience, CBC-Procos has doubled its market share in generic drugs over the last five years, significantly expanded its custom business while upgrading its technological capabilities and expanded its research and development and productions units.
“The growth of this company has been vertical in the last two to three years, so our focus is to consolidate this growth and diversify our products. Having the possibility to work with and inside a Japanese group has been an exciting honor,” Procos CEO Enrico Zodio said.
“The combination of our mutual strengths is evident and the results confirm the perfect synergy between Procos and CBC Group. We are able to meld our systems and cultures together. There is clear power in regards to advantage and merit belonging to a Japanese company,” he added.
